| US benchmarks rallied on Wednesday after the Bank of England announced it would resume bond purchases in an emergency intervention to restore stability to its financial system. The Dow gained 1.8%, and the S&P 500 added 1.9%. The Nasdaq gained 2.0%, while the small-cap Russell 2K jumped 3.1%. The New Crypto Boom is Finally Hereð¥ https://dorktra.de/57DWYY bð¥
A new opportunity is emerging in the crypto market.
One that only happens when the market is down. I'm calling it "Bitcoin 2.0"... and⦠as usual⦠it's the investors who get in while the market is down who will claim the lion's share of the spoils. If you'd like to find out how to be one of them⦠Get My Step-by-Step "Bitcoin 2.0" Blueprint Here. Government bonds are selling off globally in response to the Bank of England's emergency bond purchasing measures.Porsche became the world's most valuable automaker after the Volkswagen subsidiary's IPO valued the company at $73 billion. Welltower [WELL] - Last Close: $65.42 Welltower is rebounding from a new low in this morning's premarket. The senior housing REIT set a new 52-week low in Wednesday's trading session, when share prices touched $64.04. However, shares recaptured some of their lost ground before the closing bell, and the stock seems to be carrying some momentum into today's premarket. WELL is one of this morning's top S&P 500 stocks, with a 3.0% gain in early-morning trading. My Take: This chart could be worth watching. WELL is in a pronounced downtrend, but today's rebound could be a pivot point for the REIT stock. Axcella Health [AXLA] - Last Close: $1.73 Axella Health is on the move after a clinical update. The clinical-stage biotech company unveiled interim data from a Phase 2b EMMPACT study of AXA1125 in nonalcoholic steatohepatitis (NASH) patients. The study found the drug produced clinically and statistically significant improvements in liver stiffness, according to non-invasive liver scanning data. Subjects also experienced significant improvements in liver cell inflammation at both dosing levels of AXA1125. The interim data also showed the drug continues to present a safe and well-tolerated profile. AXLA is trading actively with a 14.4% gain. My Take: The interim data looks good, and there could be more catalysts in this stock's future if they can push AXA1125 to market. However, a lot can happen between now and then, so don't get tripped up playing around with this micro-cap biotech stock. Windtree Therapeutics [WINT] - Last Close: $0.3203 Windtree is surging on upbeat drug data. The clinical-stage biopharma firm announced late Wednesday that Phase 2 study results showed its istaroxime cardiogenic shock treatment met its primary endpoint. Windtree's drug candidate produced a "substantial increase" in the amount of blood pumped from the heart without increasing the heart rate. The study also met a key secondary endpoint evaluating cardiac function. The promising clinical results lifted WINT to a 41.4% premarket gain, and it's this morning's most active stock. My Take: This is a tiny biotech company that has struggled in 2022, but good things could be ahead if WINT can get its therapy to market. Senti Biosciences [SNTI] - Last Close: $1.40 A bullish analyst note is giving Senti Bio a premarket boost. Bank of America Securities analyst Greg Harrison initiated coverage on the micro-cap biotech stock in today's session with a "buy" rating and a price target of $7. Harrison's price target represents a 400% upside from the stock's Wednesday closing price. Details of Harrison's analysis weren't immediately available, but the market is responding to his bullish take on the company. SNTI is up 32.1% on active premarket trading volume. My Take: This seems like a big move for an analyst upgrade, so maybe there's something else in play here. I would avoid this one because the rally seems overdone, and you don't want to get caught on the wrong end of a pullback. | 